New hope for transplant patients with hepatitis b: safer drug switch under study
NCT ID NCT05410496
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at switching kidney or liver transplant patients with chronic hepatitis B to a drug called tenofovir alafenamide (TAF). The goal is to see if TAF is safer for the kidneys, controls the virus well, and is easier for patients to stick with. The study involves 52 adults who have already had a transplant and are on other hepatitis B medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tenofovir alafenamide (TAF)
- What this could lead to
- If successful, this could offer a safer and more effective way to control hepatitis B in transplant patients, potentially improving kidney function and medication adherence.
- What could go wrong
- This is a small, single-center study with only 52 participants, so results may not apply to everyone. It's also a switch therapy, not a cure, and long-term risks remain unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan, 40705, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a Decades-Old drug reverse pancreatic scarring?
- Could KP405 offer a new way to tackle Parkinson's?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus